These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 36282260)

  • 1. Newer Pharmacologic Treatments for Type 2 Diabetes.
    Laine C; Moyer DV; Qaseem A
    Ann Intern Med; 2024 Jul; 177(7):968-969. PubMed ID: 38801779
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter by Groothof et al Regarding Article, "Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial".
    Groothof D; Post A; Bakker SJL
    Circulation; 2022 Jul; 146(2):e5-e6. PubMed ID: 35858158
    [No Abstract]   [Full Text] [Related]  

  • 3. [Not Available].
    Chatzipetrou V
    Rev Med Suisse; 2024 Jun; 20(880):1277. PubMed ID: 38938141
    [No Abstract]   [Full Text] [Related]  

  • 4. Sodium-glucose cotransporter 2 inhibitors for macroalbuminuria: A new indication.
    Bloomgarden Z; Handelsman Y
    J Diabetes; 2020 Jan; 12(1):8-9. PubMed ID: 31722441
    [No Abstract]   [Full Text] [Related]  

  • 5. SGLT2 inhibitors for primary prevention of cardiovascular events.
    Raz I; Cernea S; Cahn A
    J Diabetes; 2020 Jan; 12(1):5-7. PubMed ID: 31755238
    [No Abstract]   [Full Text] [Related]  

  • 6. Determining When to Recommend Glucose-Lowering Drugs That Reduce Cardiovascular Risk.
    Robertson S
    Am Fam Physician; 2022 Jan; 105(1):10-12. PubMed ID: 35029936
    [No Abstract]   [Full Text] [Related]  

  • 7. For Patients with Type 2 Diabetes Mellitus Who Are Taking a GLP-1 Receptor Agonist, an SGLT2 Inhibitor May Be Preferred to a Sulfonylurea as Add-on Therapy.
    Ebell MH
    Am Fam Physician; 2021 Oct; 104(4):424. PubMed ID: 34652104
    [No Abstract]   [Full Text] [Related]  

  • 8. Trial Compares Glucose-Lowering Drugs for Type 2 Diabetes.
    Slomski A
    JAMA; 2022 Oct; 328(16):1581. PubMed ID: 36282260
    [No Abstract]   [Full Text] [Related]  

  • 9. Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms.
    Bajaj HS; Zinman B
    Physiology (Bethesda); 2018 May; 33(3):197-210. PubMed ID: 29638185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical considerations when adding a sodium-glucose co-transporter-2 inhibitor to insulin therapy in patients with diabetes mellitus.
    Tan K; Chow WS; Leung J; Ho A; Ozaki R; Kam G; Li J; Choi CH; Tsang MW; Chan N; Lee KK; Chan KW
    Hong Kong Med J; 2019 Aug; 25(4):312-319. PubMed ID: 31416990
    [No Abstract]   [Full Text] [Related]  

  • 11. [Application of new glucose lowering drugs: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors].
    Verburg AFE; van den Donk M; Wiersma T
    Ned Tijdschr Geneeskd; 2019 Jan; 163():. PubMed ID: 30676706
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.